Neuropharmacology Core

神经药理学核心

• 批准号: 10436858
• 负责人: KENNETH J SUFKA
• 金额: $ 29.41万
• 依托单位: UNIVERSITY OF MISSISSIPPI
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10436858
• 关键词: Acute; Animal Model; Antiepileptic Agents; Anxiety; Award; Behavioral; Binding; Biochemical; Biological; Biological Assay; Body Temperature; Businesses; Cannabinoids; Catalepsy; Cell Culture Techniques; Cells; Centers for Disease Control and Prevention (U.S.); Centers of Research Excellence; Characteristics; Cognition; Collaborations; Communities; Core Facility; Development; Differentiation and Growth; Education; Ensure; Enzymes; Equipment; Experimental Designs; Fee-for-Service Plans; Feedback; G-Protein-Coupled Receptors; Goals; Grant; In Vitro; Infrastructure; Lead; Leadership; Locomotion; Mental Depression; Mississippi; Modeling; Molecular; Monitor; Monoamine Oxidase A; Natural Products; Neuraxis; Neurons; Neuropharmacology; Neurosciences; Nociception; Opioid; Pharmacology; Pharmacy Schools; Phase; Phenotype; Positioning Attribute; Postdoctoral Fellow; Property; Publications; Quality Control; Rattus; Research; Research Personnel; Resource Sharing; Rodent; Scientist; Services; Signal Pathway; Structure; Structure of thyroid parafollicular cell; Surveys; Techniques; Toxic effect; Training; Universities; Zebrafish; base; behavior test; behavioral pharmacology; biological systems; drug development; drug seeking behavior; esterase; experience; experimental study; flexibility; in vitro Assay; in vivo; instrumentation; meetings; mouse model; multidisciplinary; neuropeptide FF; neuroprotection; neurotoxicity; outreach; programs; radioligand; receptor binding; response; synthetic drug

PROJECT SUMMARY/ABSTRACT The Center of Research Excellence in Natural Products Neuroscience (CORE-NPN) at The University of Mississippi School of Pharmacy (UM), initiated ten years ago through a COBRE grant, has developed a multidisciplinary team committed to evaluating the effects of natural products on the central nervous system (CNS). The Neuropharmacology Research Core of the COBRE CORE-NPN program represents a shared resource serving biomedical investigators / users with specialized services and training in neuropharmacological bioassays based on (a) competitive radioligand receptor binding, (b) modulation of molecular/biochemical target functions (c) cell-based phenotypic & functional responses and (d) in vivo behavioral pharmacology. This was originally two Cores, in vitro and in vivo pharmacology, in Phases I and II, with strong utilization by investigators and strong collaboration between the two. In Phase III, it has been determined that these Cores would best serve the program as one functional unit. Furthermore, by the end of Phase III, the Core is projected to be largely sustainable with efforts focused on understanding neuropharmacological properties of lead biological extracts or purified compounds and how they interact with biological systems. Efforts have been focused on expanding the core capabilities by increasing both in vitro and in vivo assays that are available to users, thereby increasing the numbers of projected users served. A fee-for-service/chargeback business model will be implemented during Phase III to ensure sustainability post Phase III. Specific Core services include radioligand binding and functional assays for cannabinoid, opioid, and Neuropeptide FF G protein-coupled receptors (GPCRs), as well as enzyme assays, phenotypic neuronal cell cultures-based assays, and analysis of neuropharmacological signaling pathways. Moreover, the Core offers a battery of acute behavioral rodent and zebrafish assays to evaluate natural product extracts and purified compounds in vivo. New in vitro assays and animal models will continue to be developed to support user needs, which ultimately broadens the overall scope and user-base for the Core. The Core is positioned to become a leader in neuropharmacological services based on natural product and synthetic drug development campaigns. We plan to achieve this through the following Specific Aims: 1) To enhance the research of the COBRE CORE-NPN and the associated community through state-of-the-art equipment, cutting-edge techniques, and scientific expertise; 2) To advance an infrastructure of developmental services to facilitate COBRE CORE-NPN research and the associated community by continual refinement and addition of assays through user input. 3) To accelerate a long-term plan for sustainability of the Core through expansion of the user base, integration of a fee-for-service structure, institutional support, and adaptation to changes by monitoring the needs of the users.

项目概要/摘要 英国大学天然产物神经科学卓越研究中心 (CORE-NPN) 密西西比药学院 (UM) 十年前通过 COBRE 资助发起，开发了一种 多学科团队致力于评估天然产物对中枢神经系统的影响 （中枢神经系统）。 COBRE CORE-NPN 计划的神经药理学研究核心代表了一个共享的 为生物医学研究人员/用户提供神经药理学专业服务和培训的资源 基于 (a) 竞争性放射性配体受体结合、(b) 分子/生化靶标调节的生物测定 功能（c）基于细胞的表型和功能反应以及（d）体内行为药理学。这是 最初有两个核心，体外和体内药理学，处于 I 期和 II 期，被研究人员广泛利用 以及两者之间的强有力的合作。在第三阶段，已确定这些核心最适合 程序作为一个功能单元。此外，到第三阶段结束时，预计核心将主要 可持续发展，重点是了解先导生物提取物的神经药理学特性或 纯化的化合物以及它们如何与生物系统相互作用。努力的重点是扩大 通过增加用户可用的体外和体内测定的核心能力，从而提高 预计服务的用户数量。期间将实施按服务收费/退款业务模式 第三阶段确保第三阶段后的可持续性。具体的核心服务包括放射性配体结合和功能 大麻素、阿片类药物和神经肽 FF G 蛋白偶联受体 (GPCR) 以及酶的检测 测定、基于表型神经元细胞培养的测定以及神经药理学信号分析 途径。此外，Core 还提供一系列急性行为啮齿动物和斑马鱼检测来评估 体内天然产物提取物和纯化化合物。新的体外测定和动物模型将继续 旨在支持用户需求，最终扩大核心的整体范围和用户基础。 The Core 定位于成为基于天然产品和药物的神经药理学服务的领导者。 合成药物开发活动。我们计划通过以下具体目标来实现这一目标： 1) 通过最先进的技术加强 COBRE CORE-NPN 和相关社区的研究 设备、尖端技术和科学专业知识； 2）推进发展基础设施建设 通过不断完善和促进 COBRE CORE-NPN 研究和相关社区的服务 通过用户输入添加分析。 3) 通过以下方式加快核心可持续发展的长期计划 扩大用户基础、整合按服务付费的结构、机构支持以及适应 通过监控用户的需求来进行更改。